Condition: Renal Cell Carcinoma (Kidney Cancer) · Kidney Cancer Metastatic · Renal Cell Carcinoma Metastatic · Sponsor: Sun Yat-sen University
This phase III randomized controlled trial evaluates the efficacy of stereotactic body radiation therapy (SBRT) in oligometastatic renal cell carcinoma. The study aims to determine if the addition of SBRT to standard systemic therapy prolong survival compared to the standard systemic therapy alone. In addition, the study will explore the impact of this combined modality therapy on patients' toxicity and quality of life. The researchers will compare SBRT plus standard systemic therapy to standard systemic therapy alone, which is targeted agents and immunotherapy in this case, to determine if SBRT could prolong survival.
This description comes directly from the study's public registry record.
Liru He, PhD · 0086-13631365597 · helir@wy.sysucc.org.cn
Fangjian Zhou, PhD · 0086-13922735659 · zhoufj@wy.sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Union Hospital, Fujian Medical University | Fuzhou, Fujian, China | Recruiting |
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Wuhan, Hubei, China | Recruiting |
| The First Hospital of Jilin University | Changchun, Jilin, China | Recruiting |
| West China Hospital, Sichuan University | Chengdu, Sichuan, China | Recruiting |
| The First Affiliated Hospital of Wenzhou Medical University | Wenzhou, Zhejiang, China | Recruiting |
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing, China | Not Yet Recruiting |
| Peking University First Hospital | Beijing, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06726421